SCBIO

What SCBIO does

SCBIO (SCBio Co., Ltd., 주식회사 에스씨바이오) is a South Korean clinical-stage biopharmaceutical company founded in October 2021 and headquartered at 94-14 Techno 2-ro, Yuseong-gu, Daejeon, with a Seoul clinical development office in Gangnam-gu. The company develops small molecule-based immunotherapeutics for cancer and related diseases, targeting tumor immune evasion mechanisms via proprietary CD73 and Sirt6 modulators (SCB001 for CRC/NSCLC, SCB002 for NSCLC/PDAC) and a next-generation antibody-drug conjugate (ADC) platform (SCB003, SCB010) that uses immune-oncology payloads rather than traditional cytotoxic toxins to minimize toxicity. The company was founded by CEO Chang Hoon Lee (Ph.D. in Immunology, SUNY Buffalo) through technology transfer from the Korea Research Institute of Chemical Technology (KRICT) and operates with 25 specialized professionals, an in-house humanized mouse model facility (7,000 mice capacity), and integrated compound synthesis and pharmacokinetics capabilities.

SCBIO's pipeline extends beyond oncology into idiopathic pulmonary fibrosis (SCB008, Sirt6-targeting), with preclinical data showing 2x efficacy versus Nintedanib and Boehringer Ingelheim's Nerandomilast plus zero liver toxicity. The company also holds Korean commercialization rights to melflufen (Pepaxti/Phepaksti), a peptide-drug conjugate from Swedish biotech Oncopeptides AB for relapsed/refractory multiple myeloma, currently pursuing Korean orphan drug approval. Melflufen offers a T-cell independent mechanism effective in patients who fail CAR-T and bispecific antibody therapies, with pivotal OCEAN study data showing PFS improvement to 9.3 months vs 4.6 months in the target population (HR=0.58, p=0.0001).

The company's revenue model is a hybrid pipeline of licensing royalties from out-licensed candidates, direct product sales from melflufen upon Korean approval (priced at approximately 18 million KRW per cycle with patient support programs), and technology licensing-out deals. SCBIO is currently pre-revenue, having raised cumulative funding of KRW 31 billion (~$23M USD) across three venture rounds (Pre-Series A in Oct 2022, Series A in May 2023, Series B in Sep 2025). The company is targeting a KOSDAQ listing in 2027 and positions its go-to-market through direct hospital engagement in Korea, annual JP Morgan Healthcare Conference participation, and an internal AI-based drug discovery research initiative.

Name

SCBIO

Legal name

주식회사 에스씨바이오

Website

https://sc-bio.co.kr

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

SCBIO is a South Korean clinical-stage biotech founded in 2021 developing small molecule immunotherapeutics for cancer and idiopathic pulmonary fibrosis, with a pipeline including CD73 and Sirt6 inhibitors, next-generation ADCs, and Korean commercialization rights to melflufen for multiple myeloma.

Ownership category

akta.pro rank

Product category

Immuno-Oncology Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Immuno-oncology drugs
• Small molecule therapeutics
• Cancer immunotherapy
• Peptide drug conjugates
• Targeted anticancer agents

Headquarters

HQ city

Daejeon

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pipeline Drug Development: Pre-revenue biotech developing novel immunotherapy and targeted anticancer drugs. SCB001, SCB002 in preclinical development with IND targets for 2024. SCB008 for IPF entering Phase 1 clinical trials.
2. Melflufen Commercialization: Secured domestic rights for melflufen (Pepaxti) from Oncopeptides AB for multiple myeloma treatment. Currently undergoing Korean orphan drug approval process. Revenue expected from product sales upon approval.
3. Technology Licensing-Out: Strategic focus on licensing-out pipeline candidates following clinical results. Targeting global technology licensing deals as part of growth strategy.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

SCBIO develops small molecule-based immunotherapeutics and targeted anticancer drugs, with a pipeline including SCB001 (CD73 inhibitor for CRC/NSCLC), SCB002 (Sirt6 targeting for NSCLC/PDAC), SCB008 (IPF treatment), and next-generation ADC platforms. The company also holds domestic Korean rights for Melflufen (Pepaxti), a peptide-drug conjugate for relapsed/refractory multiple myeloma licensed from Oncopeptides AB, with plans for direct hospital distribution upon orphan drug approval.

Product overview

SCBIO is a biotech company specializing in immuno-oncology drug development with a portfolio of pipeline candidates and licensed products. The pipeline includes SCB001 (CD73-targeting immunotherapy for CRC/NSCLC), SCB002 (Sirt6-targeting for NSCLC/PDAC), SCB008 (IPF treatment), and next-generation ADC platforms (SCB003, SCB010). The company also distributes Melflufen (Phepaksti), a peptide-drug conjugate for multiple myeloma licensed from Oncopeptides AB. SCBIO operates with an integrated drug discovery system including AI-based research capabilities, in-house compound synthesis facilities, animal testing labs (7,000 mice capacity), and pharmacokinetics evaluation capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• SCB001 CD73-targeting small molecule immunotherapy candidate for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). Demonstrated superior efficacy and safety compared to Novartis's NZV930 and Arcus's Quemliclustat in animal models.
• SCB002 Sirt6-targeting small molecule for non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). Regulates innate immune activity; demonstrated 100% complete remission in animal studies when combined with standard chemotherapy (Gemcitabine/Paclitaxel).
• SCB003 Next-generation Antibody-Drug Conjugate (ADC) platform technology for targeted cancer therapy, utilizing immune-oncology payloads instead of traditional cytotoxic toxins to minimize toxicity.
• SCB008 Idiopathic Pulmonary Fibrosis (IPF) treatment targeting Sirt6 protein with anti-fibrotic and anti-inflammatory properties. Demonstrated greater than 2x efficacy compared to current standard treatment Nintedanib and Boehringer Ingelheim's Nerandomilast in preclinical studies, with zero liver toxicity observed.
• SCB010 Next-generation ADC platform utilizing immune-oncology technology instead of traditional cytotoxic toxins to minimize toxicity.
• SCB007 Discovery stage pipeline candidate with undisclosed indication.
• SCB011
• Melflufen (Phepaksti/Pepaxti) Peptide-drug conjugate (PDC) for relapsed/refractory multiple myeloma (RRMM). Developed by Oncopeptides AB; SCBIO secured domestic Korean rights. T-cell independent mechanism effective even in patients who do not respond to CAR-T or bispecific antibodies. Administered as a 30-minute IV infusion once monthly.
• AI-based Drug Discovery Research Center Internal AI-powered research facility for accelerating drug discovery through computational approaches, including bioinformatics and target identification. Recruits AI-based drug research institute leaders and staff.

Quantifiable outcome

• SCB001 demonstrated superior efficacy and safety vs Novartis NZV930 and Arcus Quemliclustat in animal models
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature6 records

Partnerships

Four partnerships are on record, tiered major and core.

• Australian Clinical SitesmajorStrategic or Co-development Partner · 1 January 2026Phase 1 clinical trial site for SCB008 IPF treatment in Australia (planned).
• Oncopeptides ABcoreOEM/ Whitelabel/ Licensing PartnerSecured domestic (Korea) rights for melflufen (Pepaxti) from Swedish biotech Oncopeptides AB for treatment of relapsed/refractory multiple myeloma. Currently pursuing Korean orphan drug approval.
• Korea Research Institute of Chemical Technology (한국화학研究院)coreStrategic or Co-development PartnerTechnology transfer from KRICT in November 2021. CEO Lee Chang-hoon maintains position as senior researcher. Foundation of company's research capabilities and IP portfolio.
• Seoul National University HospitalcoreStrategic or Co-development PartnerPhase 1 clinical trial site for SCB008 idiopathic pulmonary fibrosis treatment in Korea.

Scale indicators6 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Arcus Biosciences: US clinical-stage immuno-oncology company developing Quemliclustat (CD73 inhibitor). Direct competitor to SCBIO's SCB001 program with the same target and overlapping indications.
• Bridge Biotherapeutics: Korean clinical-stage biotech developing therapies for fibrotic diseases and oncology. Comparable as a Korean biotech peer targeting IPF and immuno-oncology indications.
• LegoChem Biosciences: Korean biotech with proprietary ADC platform technology (ConjuAll). Comparable as a Korean biotech peer developing next-generation antibody-drug conjugates with focus on reduced toxicity profiles.
• Oncopeptides AB: Swedish biotech that developed and licensed melflufen (Pepaxti) to SCBIO for the Korean market. Direct counterparty in SCBIO's lead commercialization asset and most relevant peer given the same molecule.

Broad incumbents

• Novartis: Global pharma developing NZV930 (CD73 inhibitor) for immuno-oncology. Direct competitor to SCB001 with vastly greater resources and clinical development capability in the same target class.
• Boehringer Ingelheim: Global pharma marketing Nintedanib (Ofev) as standard of care for IPF. Competes directly with SCBIO's SCB008 IPF candidate and is also developing next-generation IPF therapy Nerandomilast.
• Daiichi Sankyo: Global leader in ADC technology with Enhertu and Datroway. Relevant as established ADC platform incumbent that SCBIO's next-generation ADC platform (SCB003, SCB010) aims to compete with or partner into.

Regional players

• ABL Bio: Korean clinical-stage biotech focused on bispecific antibodies for immuno-oncology and neurodegenerative diseases. Comparable Korean biotech peer with similar oncology pipeline focus and funding stage.
• Genexine: Korean biotech developing immuno-oncology and fusion protein therapeutics. Comparable Korean biotech peer with multiple pipeline candidates in oncology and experience navigating Korean regulatory and capital markets.
• Yuhan Corporation: Major Korean pharmaceutical company with oncology pipeline including targeted therapies and immunotherapies. Comparable as a Korean pharmaceutical company developing innovative oncology drugs with broader commercialization capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SCBIO